However, the approval of the CCR5 antagonist maraviroc and the CXCR4 antagonist plerixafor as well as ongoing clinical trials against diverse diseases such as rheumatoid arthritis, chronic obstructive pulmonary disease or Crohn’s disease show the great potential of therapies modulating the chemokine response. This evidence concerns the gene CXCR4 and Crohn disease.